AI Driving Ursodeoxycholic Acid Market Growth, USD 463.2 Million Increase Projected 2024-2028 Due To Rising Liver Transplants - Technavio Report
Report with the AI impact on market trends- The global ursodeoxycholic acid market size is estimated to grow by USD ...
infectiousdiseaseadvisor.com1d
UDCA Is a Possible Adjunct Therapy for COVID-19 in CLD, Including PBC
In patients with chronic liver disease, including PBC, ursodeoxycholic acid shows promise as an adjunctive therapy for COVID-19 infection.
Scientists synthesize a prebiotic carrier assists regorafenib in treating colorectal cancer
In a study published in Advanced Functional Materials, a research team from the Shanghai Institute of Materia Medica (SIMM) ...
The Pharma Letter12h
Ipsen’s Iqirvo approved in Europe
The European Commission has conditionally approved the marketing application submitted by Ipsen for Iqirvo (elafibranor) 80mg ...
Medpage Today on MSN8d
Approved Liver Disease Drug Has No Clinical Benefit, FDA Panel Says
Obeticholic acid had been awarded accelerated approval by the FDA in May 2016 as a second-line treatment for PBC patients not ...
Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade
European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for primary biliary ...
Ipsen: European Commission Grants Conditional Marketing Authorization For Iqirvo
Ipsen (IPSEY) announced the European Commission has conditionally approved Iqirvo 80mg tablets for the treatment of primary biliary ...
Hosted on MSN23d
How Gallbladder Sludge Forms
People who have documented gallbladder sludge may be candidates for treatment with Actigall (ursodeoxycholic acid). This ...
Medpage Today on MSN10d
FDA Reviewers Skeptical of Ocaliva for Rare Bile Duct Disease
Obeticholic acid was given accelerated approval by the FDA in May 2016 as a second-line treatment for PBC patients not ...
News Medical on MSN5d
Mitochondria at the crossroads of cholestatic liver injury: Targeting novel therapeutic avenues
Bile acids are byproducts of cholesterol metabolism in the liver and constitute the primary components of bile. Disruption of ...
Daily2d
Goa FDA issues advisory on 156 banned FDCs
Panaji: Following a recent ban on 156 fixed-dose combinations by the Central Government, the Directorate of Food and Drugs ...
Ipsen Pharma: Ipsen's Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade
European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for primary biliary cholangitis (PBC), a rare liver diseaseApproval follows posit ...